⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZYME News
Zymeworks Inc.
Form 8-K
sec.gov
ZYME
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
globenewswire.com
RPRX
ZYME
Form 8-K
sec.gov
ZYME
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
globenewswire.com
RPRX
ZYME
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
globenewswire.com
ZYME
RPRX
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ZYME
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ZYME
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
globenewswire.com
ZYME
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
globenewswire.com
ZYME